Salix, Mitsubishi Tanabe Pharma to Develop and Commercialize MT-1303 for IBD
News
Mitsubishi Tanabe Pharma and Salix Pharmaceuticals have entered into an exclusive licensing agreement for MT-1303 (amiselimod), a therapeutic agent for autoimmune diseases including inflammatory bowel disease (IBD) and ulcerative colitis. ... Read more